NEWRON PHARMACEUT. EO-20 Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

NEWRON PHARMACEUT. EO-20 capital reinvestment ratio. NEWRON PHARMACEUT. EO-20 (NP5) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow (€32.35 Million) in capital expenditures (€48.00K). Check NEWRON PHARMACEUT. EO-20 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

€32.35 Million

EUR

Capital Expenditures

€48.00K

EUR

Data as of

Dec 2025

Most recent filing

Capital Reinvestment Ratio of NEWRON PHARMACEUT. EO-20 (2025–2025)

Capital reinvestment ratio of NEWRON PHARMACEUT. EO-20 from 2025 to 2025. This chart tracks NEWRON PHARMACEUT. EO-20's Capital Reinvestment Ratio across 1 annual periods. Also explore NP5 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

NEWRON PHARMACEUT. EO-20 Capital Reinvestment Ratio by Year (2025–2025)

NEWRON PHARMACEUT. EO-20 capital reinvestment ratio by year from 2025 to 2025. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 (NP5) cash conversion ratio.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2025	0.00x	€32.35 Million	€48.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow